Cytosorbents vs Nephros
CTSO and NEPH side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CTSO and NEPH compare
Cytosorbents is the larger company, worth 10 times as much as Nephros ($336M against $33.3M).
Nephros grew revenue faster over the last twelve months (20.4% versus 3.1% for Cytosorbents).
Nephros keeps more of each dollar of sales as profit, with a net margin of 8.9% compared with −48.9% at Cytosorbents.
Nephros scores higher on the StockData Score (13 against 2 for Cytosorbents), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CTSO | NEPH |
|---|---|---|
| Size and price | ||
| Market cap | $336M | $33.3M |
| Share price | $5.34 | $3.07 |
| Change, 1 year | −63.0% | −28.4% |
| Change, 5 years | −94.9% | −58.6% |
| Beta (5Y) | 0.96 | 0.58 |
| Employees | 129 | 36 |
| StockData Score | ||
| Total score | 2 | 13 (better) |
| Valuation score | 0 | 4 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 1 | 2 (better) |
| Health score | 0 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 17.1× |
| P/S | 9.0× | 1.5× (better) |
| EV/EBITDA | – | 14.8× |
| FCF yield | −2.8% | – |
| Fair value | – | $4.25 |
| Margin of safety | – | 27.7% |
| Growth | ||
| Revenue growth (TTM) | 3.1% | 20.4% (better) |
| Revenue growth, 5Y average | −2.0% | 17.0% (better) |
| Net income growth (TTM) | – | 29.0% |
| EPS growth (TTM) | – | 38.5% |
| Profitability | ||
| Gross margin | 71.6% (better) | 60.5% |
| Operating margin | −34.7% | 8.5% (better) |
| Net margin | −48.9% | 8.9% (better) |
| FCF margin | −25.0% | – |
| Return on equity | −336% | – |
| Return on invested capital | −73.4% | – |
| Financial health | ||
| Current ratio | 0.66 | 5.50 (better) |
| Altman Z-score | −7.07 | −3.01 (better) |
| Piotroski F-score | 3 | 7 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 1.3% | 48.9% |
| Held by insiders | 2.5% | 9.2% |
| Insider net buying, 12 months | $269K | – |
| Short interest, % of float | 0.22% | 0.12% |
Go deeper
- CTSO stock overview
- CTSO income statement
- CTSO valuation and score
- NEPH stock overview
- NEPH income statement
- NEPH valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.